当前位置：   首页 > 需求大厅

 >  生产研发 

 >  工艺技术 

寻找一种载体某些细胞或分子如蛋白质，DNA，RNA，和microRNA，用这些载体来制备高选择性的靶向药物，给药的方法是让药物化合物给药和输送到身体的病灶而达到治疗效果。具体的要求请看下面链接：https://www.innocentive.com/ar/challenge/9933675 AWARD: $30,000 USD | DEADLINE: 2/17/15 | ACTIVE SOLVERS: 108 | POSTED: 1/16/15 Exosomes are membrane-bound vesicles that are produced by many, if not all cell types. Exosomes are able to selectively target certain cells and deliver molecules such as proteins, DNA, RNA, and microRNA. These vesicles are thought to have great potential for targeted drug delivery. The Seeker desires innovative methods for exosome drug loading without significant disruption of the membrane components and properties of the exosome. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933675 Challenge Overview Drug delivery is the method by which pharmaceutical compounds are administered and transported in the body to achieve therapeutic efficacy. Recently, exosomes have been identified as a novel method to deliver drugs in a targeted manner and their potential is derived from natural components such as specific proteins/lipids contained in the membrane of exosomes. Successful delivery of substantial amounts of therapeutic drugs using exosomes is critically dependent on a highly efficient and broadly applicable methodology for loading exosomes with the therapeutic agent, however at present no such technology is available. The Seeker is looking for one or more technologies that will facilitate exosome drug loading without significant disruption of the membrane components and properties of the exosome.   [更多]

资金规模：2000万元 技术要求：工业化成熟可靠的生产技术。有此产品生产 技术者请发产品可行性报告到我司； 中文别名： ;N,N-二甲基-4-氨基苯甲醛;4-(N,N-二甲基)氨基苯甲醛;4-二甲氨基苯甲醛;4-(二甲氨基)苯甲醛;对二甲胺基苯甲醛; 英文名称： 4-Dimethylaminobenzaldehyde 英文别名： ;Ehrlichs;N,N-dimethyl-4-amino benzaldehyde;4-(N,N-Dimethyl)aminobenzaldehyde;p-Dimethylaminobenzaldehyde;4-dimethyl amino benzaldehyde;4-amino-2,3-dimethylbenzaldehyde;P-(Dimethylamino)benzaldehyde; EINECS号： 202-819-0 分子式： C9H11NO 分子量： 149.1897 InChI： InChI=1/C9H11NO/c1-6-7(2)9(10)4-3-8(6)5-11/h3-5H,10H2,1-2H3 密度： 1.097g/cm3 熔点： 70-75℃ 沸点： 305.7°C at 760 mmHg 闪点： 138.7°C 水溶性： 0.3 g/L (20℃)   [更多]

求助丙烯基乙醚的合成工艺,化合物CA登记号(CAS):928-55-2   [更多]

2000元 罗红霉素胶囊75mg 全粉末填充成熟工艺 我公司罗红霉素胶囊75mg 工艺在胶囊填充时装量差异不稳定，工艺复杂，现悬赏求助不经制粒工序，原料加辅料混合直接填充的工艺。工艺走通后给予赏金2000元。   [更多]

苦木的化学成分研究资料------在苦木中分离的化合物，要有具体的分离方法，每个化合物有原始打印的H谱和C谱，有紫外红外更好。有这些资料的联系我，高价格商谈！   [更多]

（1）4-甲氧基-5羟基-铁屎米酮 cas：18110-86-6 （2）4，5-二甲氧基铁屎米酮 cas:18110-87-7 (3) 3-甲基-铁屎米酮-2,6-二酮 有做过苦木生物碱分离的研究生，手里有标准品的我们可以购买，如果能给我们分离也可以，需求量每种40-60mg。价格我们商谈！价钱好说   [更多]

Sibutramine的生产工艺   [更多]

可使生物降解的长效制剂微胶囊技术是一种药物控释技术。在授控的较长的一段时间药物缓慢释放。在过去的二十年中，武田公司已经完善了其专有技术，即具有微胶囊的长效制剂，能在人体的6个多月保持血药浓度。武田希望能有一种技术，即在确定的治疗药物，使用缓释长效制剂微胶囊技术能在任何人体组织上定向使用。具体如下：{https://www.innocentive.com/ar/challenge/9933674} AWARD: varies | DEADLINE: 1/26/15 | ACTIVE SOLVERS: 28 | POSTED: 12/10/14 Depot formulation using a biodegradable microcapsule is one technique for the controlled delivery of pharmaceuticals. The drug is slowly released over an extended period of time in a controlled manner. During the past two decades, Takeda has perfected its proprietary technology, which features a microcapsule depot formulation that maintains drug plasma levels for more than 6 months in humans. Takeda wishes to identify therapeutic agents that will benefit from sustained release through depot formulation using microcapsule technology. This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a Takeda funded collaborative partnership. A finder’s fee of $3,000 will be offered at the Seeker’s sole discretion to submission(s) that provide contacts which meet the criteria of the Challenge. Source: InnoCentive Challenge ID: 9933674 Challenge Overview Takeda is well known for its superior depot formulation using microcapsule technology. Controlled sustained release of drugs is achieved using either PLGA (poly-lactic-co-glycolic acid) or PLA (poly-lactic acid) polymer to make microspheres. This core technology is capable of producing injectable formulations that are biodegradable and release drugs over a period of weeks to months. By formulating drugs using this best-in-class approach, Takeda hopes to apply their microcapsule technology to improve the efficacy and safety of known therapeutics compared to the existing administration methods, while providing alternative treatment options to patients with unmet medical needs. In other words, Takeda makes this   [更多]

我公司有“达巴万星”（Dalbavancin）及“奥利万星”（Oritavancin）原料药生产工艺，这两个产品2014年已经被FDA批准生产为最新抗菌及抗生素新药，前景广泛，现向国内企业寻求合作。 产品介绍： 达巴万星（Dalvance）于 5月23日被美国FDA批准一种新的抗菌药物新药，用于治疗由象金黄色葡萄球菌（包括甲氧西林敏感的和耐甲氧西林菌株）和化脓性链球菌等某些敏感细菌引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）。Dalvance是第一个接受FDA批准作为合格的传染病产品[Qualified Infectious Disease Product (QIDP)]设计的药物。Dalvance被认定为合格传染病产品（Qualified Infectious Disease Product，QIDP）而获得FDA批准的首个药物。根据安全和创新法案的现行抗生素激励（GAIN）条款，Dalvance获得了QIDP认定，因为它是一种用于治疗严重或危及生命的感染的抗菌或抗真菌人用药品。 FDA的药物评价和研究中心抗微生物产品室主任Edward Cox，M.D.，M.P.H说：“今天的批准证实FDA鼓励增加发展和批准新抗细菌药物的承诺，提供医生和患者重要新治疗选择”。 奥利万星（Oritavancin），于8月6被 FDA批准抗生素新药，用于由敏感革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌，MRSA）导致的急性细菌性皮肤和皮肤结构感染（ABSSSIs）成人患者的治疗。用于由敏感革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌，MRSA）导致的急性细菌性皮肤和皮肤结构感染（ABSSSIs）成人患者的治疗。Orbactiv是FDA批准用于ABSSSIs治疗的首个和唯一一种单剂量治疗方案的抗生素。患者仅接受一次Orbactiv输液，整个治疗方案便已结束。此次Orbactiv的获批，也代表着细菌性皮肤和皮肤结构感染疾病治疗方面远超当前临床标准的重大进步。目前，患者往往需要多次静脉输注抗生素，而Orbactiv单剂量治疗方案，将显著减少患者的剂量负担。 目前，欧洲药品管理局（EMA）正在审查Orbactiv的上市许可申请（MAA），该申请中，Medicines公司寻求批准用于复发皮肤和软组织感染（cSSTI）的治疗。欧盟委员会（EC）预计将于2015年上半年做出最终审查决定。   [更多]

中药材超细化可提高药效,一方面成本低，易于推广，另一方面可全组份入药，对珍贵药材及药效成份不明确的药材更有意义，大大节约了资源。我司急需中药材超细粉碎技术。   [更多]